Use of misoprostol in the elderly: Is the expense justified?

Drugs and Aging

Volumn 8, Issue 2, 1996, Pages 84-88

  Stucki, Gerald ^a,c   Johannesson, Magnus ^b   Liang, Matthew H ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN E1 DERIVATIVE;

AGED; ARTHRITIS; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG USE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; PHARMACOECONOMICS; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; RISK; SHORT SURVEY; STOMACH ULCER;

EID: 0030065591     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608020-00002     Document Type: Short Survey

References (24)

1. Hawkey CJ. N of 1 trials in osteoarthritis. BMJ 1995; 310: 666-7
2. Gabriel SE, Jaakkimainen L, Bombardier C. Risk of serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787-96
3. Dieppe P, Cushnaghan J, Jasani MK, et al. I. A two-year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthrilis of the knee joint. Br J Rheumatol 1993; 32: 595-600
4. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989; 96: 647-55
5. Gabriel SE, Campion ME, O'Fallon WM. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammalory drugs. Arthritis Rheum 1994; 37: 333-41
6. De Pouvourville G. The iatrogenic cost of non-steroidal antiinflammatory drug therapy. Br J Rheumatol 1995; 34 Suppl. 1: 19-24
7. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, doubleblind, placebo-controlled trial. Lancet 1988; 2: 1277-80
8. Verdickt W, Moran C, Hantzschel H, et al. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol 1992; 21: 85-91
9. Melo Gomes JA, Roth SH, Zeeh J, et al. Double-blind comparison of the efficacy and gaslroduodenal safety of diclofenac/ misoprostol, piroxicam and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993; 52: 881-5
10. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory agents. Ann Intern Med 1995; 123: 241-9
11. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking non-steroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 2061-5
12. Knill-Jones R, Drummond M, Kohli H, et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J 1990; 66: 639-46
13. Jonsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. Int J Technol Assess Health Care 1992; 8: 234-44
14. Edelson JT, Tosleson ANA. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal bleeding. JAMA 1990; 264: 41-7
15. Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993; 36: 447-59
16. Stucki G, Johannesson M, Liang MH. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? Arch Intern Med 1994; 154: 2020-5
17. Gabriel SE. Has the cost-effectiveness of misoprostol been underestimated? [letter]. Arch Intern Med 1995; 155: 1448-9
18. Fort JG, Hoffman HD. Cost-effectiveness and misoprostol [letter]. Arch Intern Med 1995; 155: 1448
19. Stucki G, Johannesson M, Liang MH. Has the cost-effectiveness of misoprostol been underestimated? [letter]. Arch Intern Med 1995; 155: 1451-2
20. International monetary fund: foreign exchange rates: 1970 to 1992. In: The world almanac and book of facts 1994. Mahwah (NJ): Funk & Wagnalls Corporation 1993: 114
21. Beck RJ, Pauker SG, Goltlieb JE, et al. I. A convenient approximation of life expectancy (the 'deal'). II. Use in medical decision making. Am J Med 1982; 73: 889-97
22. Soll AH, Isenberg JI. Duodenal ulcer diseases. In: Sleisenger MH, Fortran JS, editors. Gastrointestinal disease: pathophysiology, diagnosis and management. 3rd ed. Philadelphia (PA): WB Saunders Co, 1983
23. Walt RP. Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N Engl J Med 1992; 327: 1575-80
24. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford Medical Publications, 1987